<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39320472</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>152</Volume><PubDate><Year>2024</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Epidemiology and infection</Title><ISOAbbreviation>Epidemiol Infect</ISOAbbreviation></Journal><ArticleTitle>Omicron incidence and seroprevalence among children in Montreal, Canada, in early 2023: final results from the longitudinal EnCORE serology study.</ArticleTitle><Pagination><StartPage>e103</StartPage><MedlinePgn>e103</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e103</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0950268824000797</ELocationID><Abstract><AbstractText>Since early 2022, routine testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on symptoms and exposure history has largely ceased in Canada. Consequently, seroprevalence studies, particularly longitudinal studies, have become critical for monitoring the rate of incident SARS-CoV-2 infections and the proportion of the population with evidence of immunity. EnCORE is a longitudinal SARS-CoV-2 seroprevalence study comprising five rounds of serology testing from October 2020 to June 2023, in a sample of 2- to 17-year-olds (at baseline), recruited from daycares and schools in four neighbourhoods of Montreal, Canada. We report on SARS-CoV-2 incidence and seroprevalence among the 509 participants in the fifth and final round of the study. Seroprevalence of antibodies from either infection or vaccination was 98% (95 per cent confidence interval [CI]: 97, 99). The infection-acquired seroprevalence was 78% (95% CI: 73-82), and the incidence rate was 113 per 100 person-years (95% CI: 94-132), compared to the seroprevalence of 58% and the incidence rate of 133 per 100 person-years, respectively, in the fourth round of testing (mid-late 2022). Of the 131 participants newly seropositive for infection in Round 4, only 18 were seronegative for infection in Round 5 (median follow-up: 326 days).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Charland</LastName><ForeName>Katia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for Public Health Research, University of Montreal, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierce</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0004-2012-3515</Identifier><AffiliationInfo><Affiliation>Centre for Public Health Research, University of Montreal, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saucier</LastName><ForeName>Adrien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Public Health Research, University of Montreal, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamelin</LastName><ForeName>Marie-Ève</ForeName><Initials>MÈ</Initials><AffiliationInfo><Affiliation>Research Centre of Quebec-Université Laval, Quebec City, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbosa Da Torre</LastName><ForeName>Margot</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Public Health Research, University of Montreal, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carbonneau</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Centre of Quebec-Université Laval, Quebec City, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Cat Tuong</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Ministère de la santé et des services sociaux, Quebec City, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Serres</LastName><ForeName>Gaston</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-1592-5167</Identifier><AffiliationInfo><Affiliation>National Institute of Public Health of Quebec, Quebec City, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papenburg</LastName><ForeName>Jesse</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Montreal Children's Hospital of the McGill University Health Centre, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boivin</LastName><ForeName>Guy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Research Centre of Quebec-Université Laval, Quebec City, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quach</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departments of Microbiology, Infectious Diseases &amp; Immunology and of Pediatrics, University of Montreal, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinszer</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for Public Health Research, University of Montreal, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Junior 2 Chercheur Boursier (Zinszer)</GrantID><Agency>Fonds de Recherche du Québec - Santé</Agency><Country /></Grant><Grant><GrantID>179445</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>2021-HQ-000097</GrantID><Agency>Public Health Agency of Canada</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Epidemiol Infect</MedlineTA><NlmUniqueID>8703737</NlmUniqueID><ISSNLinking>0950-2688</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011792" MajorTopicYN="N" Type="Geographic">Quebec</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>J.P. reports grants from MedImmune, grants and personal fees from Merck and AbbVie, and personal fees from AstraZeneca, all outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39320472</ArticleId><ArticleId IdType="pmc">PMC11427972</ArticleId><ArticleId IdType="doi">10.1017/S0950268824000797</ArticleId><ArticleId IdType="pii">S0950268824000797</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zinszer K, Charland K, Pierce L, Saucier A, Hamelin M, Da Torre MB, Carbonneau J, Nguyen CT, De Serres G, Papenburg J, Boivin G and Quach C (2023) Infection‐induced seroconversion and seroprevalence of SARS‐CoV‐2 among a cohort of children and youth in Montreal, Canada. Influenza and Other Respiratory Viruses 17. 10.1111/irv.13186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13186</ArticleId><ArticleId IdType="pmc">PMC10457549</ArticleId><ArticleId IdType="pubmed">37638094</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinszer K, Charland K, Pierce L, Saucier A, McKinnon B, Hamelin M-È, Cheriet I, Da Torre MB, Carbonneau J, Nguyen CT, De Serres G, Papenburg J, Boivin G and Quach C (2023) Pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and teenagers in Montréal, Canada. International Journal of Infectious Diseases 131, 119–126. 10.1016/j.ijid.2023.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.03.036</ArticleId><ArticleId IdType="pmc">PMC10033142</ArticleId><ArticleId IdType="pubmed">36963656</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaker H (2000) Confidence curves and improved exact confidence intervals for discrete distributions. Canadian Journal of Statistics 28, 783–798. 10.2307/3315916.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/3315916</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallis JA and Turner EL (2019) Relative measures of association for binary outcomes: challenges and recommendations for the global health researcher. Annals of Global Health 85. 10.5334/aogh.2581.</Citation><ArticleIdList><ArticleId IdType="doi">10.5334/aogh.2581</ArticleId><ArticleId IdType="pmc">PMC6873895</ArticleId><ArticleId IdType="pubmed">31807416</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy TJ, Swail H, Jain J, Anderson M, Awadalla P, Behl L, Brown PE, Charlton CL, Colwill K, Drews SJ, Gingras A-C, Hinshaw D, Jha P, Kanji JN, Kirsh VA, Lang ALS, Langlois M-A, Lee S, Lewin A, O’Brien SF, Pambrun C, Skead K, Stephens DA, Stein DR, Tipples G, Van Caeseele PG, Evans TG, Oxlade O, Mazer BD and Buckeridge DL (2023) The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020–2023. Canadian Medical Association Journal, 195, E1030–E1037. 10.1503/cmaj.230249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.230249</ArticleId><ArticleId IdType="pmc">PMC10426348</ArticleId><ArticleId IdType="pubmed">37580072</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry J, Osman S, Wright J, Richard-Greenblatt M, Buchan SA, Sadarangani M and Bolotin S (2022) Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review. PLOS ONE 17, e0266852. 10.1371/journal.pone.0266852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266852</ArticleId><ArticleId IdType="pmc">PMC8993021</ArticleId><ArticleId IdType="pubmed">35395052</ArticleId></ArticleIdList></Reference><Reference><Citation>Magesh S, John D, Li WT, Li Y, Mattingly-App A, Jain S, Chang EY and Ongkeko WM (2021) Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status. JAMA Network Open 4, e2134147. 10.1001/jamanetworkopen.2021.34147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.34147</ArticleId><ArticleId IdType="pmc">PMC8586903</ArticleId><ArticleId IdType="pubmed">34762110</ArticleId></ArticleIdList></Reference><Reference><Citation>Katikireddi SV, Lal S, Carrol ED, Niedzwiedz CL, Khunti K, Dundas R, Diderichsen F and Barr B (2021) Unequal impact of the COVID-19 crisis on minority ethnic groups: a framework for understanding and addressing inequalities. Journal of Epidemiology and Community Health 75, 970–974. 10.1136/jech-2020-216061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech-2020-216061</ArticleId><ArticleId IdType="pmc">PMC8458062</ArticleId><ArticleId IdType="pubmed">33883198</ArticleId></ArticleIdList></Reference><Reference><Citation>Crocker-Buque T, Edelstein M and Mounier-Jack S (2017) Interventions to reduce inequalities in vaccine uptake in children and adolescents aged &lt;19 years: a systematic review. Journal of Epidemiology and Community Health 71 87–97. 10.1136/jech-2016-207572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech-2016-207572</ArticleId><ArticleId IdType="pmc">PMC5256276</ArticleId><ArticleId IdType="pubmed">27535769</ArticleId></ArticleIdList></Reference><Reference><Citation>Carazo S, Skowronski DM, Brisson M, Barkati S, Sauvageau C, Brousseau N, Gilca R, Fafard J, Talbot D, Ouakki M, Gilca V, Carignan A, Deceuninck G, De Wals P and De Serres G (2023) Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. The Lancet Infectious Diseases 23, 45–55. 10.1016/S1473-3099(22)00578-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00578-3</ArticleId><ArticleId IdType="pmc">PMC9491856</ArticleId><ArticleId IdType="pubmed">36152671</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>